AVADEL PHARMA Stock Analysis (NASDAQ:AVDL)

Add to My Stocks
$10.08 $0.23 (2.23%) AVDL stock closing price Jan 23, 2017 (Closing)
Watch Robo Advisor Video of AVDL Stock Analysis
AVADEL PHARMA
Updated on : Jan 23, 2017
previous close
AVDL 10.1 (0%)
S&P 500 2265.2 (0%)
Closing Price On: Jan 23, 2017
stock rating
RATING: ★★★★★★★★★★ (0/5)
Industry :
Medical-Drugs
Sector :
Medical
5 Quarter Revenue
Revenue Growth
2016-Q3
$million
%
YOY GROWTH
Compared to the industry
Long Term Growth
5 Year CAGR:
32.1%
Operating Profit
Operating Margin:
-12.7%
Sector Average:
-1.3%
5 Quarter Net Profit
Net Margins
2016-Q3
%
LTM Margin
Compared to the industry
Debt/Equity Ratio
Debt:
1M
Debt/Equity Ratio:
 0.03
Compared to the industry
Cash Flow
Operating cash flow:
-$4.8M
Net Income:
-$22.3M
PROS      CONS
Low Debt Burden
ROE
PS Valuation
Long Term Growth
Operating Margins
ROIC
FCF Margin
PE Valuation
Rating: ★★★★★★★★★★ (0/5)
Relative Valuation
AVDL PS :
2.8
Industry PS :
4.5
Sector:   Medical.   *PE adjusted for one time items.
Other Metrics
Return on Invested Capital:
-32.4%
Return on Equity:
60.7%
Free Cash Flow Margin:
-15.6%
Double Tap To Exit Full Screen
0:00
/

AVADEL PHARMA Analysis Video

3 5 2

View AVADEL PHARMA stock analysis video. This is our AVDL analyst opinion covering the buy and sell arguments for AVDL stock.

AVADEL PHARMA Stock Rating (3/5)

Our AVADEL PHARMA stock opinion is based on fundamentals of the company. This AVADEL PHARMA stock analysis is based on latest Q3 earnings for 2016. The stock price analysis takes into account a company's valuation metrics.

Should you buy AVDL stock?

  • With its debt/equity ratio of  0.03, AVADEL PHARMA has a lower debt burden when compared to the Medical average.
  • The lower PS ratio 2.8 for AVDL stock versus Medical-Drugs industry average of 4.5 is a positive for the company.
  • AVADEL PHARMA has a good Return On Equity (ROE) of 60.7%.

Should you sell AVDL stock?

  • Revenue growth of has been weak over the last 5 years.
  • AVADEL PHARMA registered a negative operating margin of -12.7% (average) over the Trailing Twelve Months (TTM).
  • Trading at a PE ratio of 38.8, AVDL stock is overvalued in comparison to industry average multiple of 21.8.
  • AVADEL PHARMA has a negative ROIC (Return on Invested Capital) of -32.4%.
  • The company has negative Free Cash Flows (FCF), with a negative FCF margin of -15.6%.

Comments on this video and AVADEL PHARMA stock